The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma

被引:3
|
作者
Tollefson, Matthew K. [2 ]
Boorjian, Stephen A. [2 ]
Lohse, Christine M. [3 ]
Blute, Michael L. [2 ]
Leibovich, Bradley C. [1 ,2 ]
机构
[1] Mayo Clin, Dept Urol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Urol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Hlth Sci Res, Rochester, MN 55905 USA
关键词
renal cell carcinoma; family history; disease progression; partial nephrectomy; SYSTEMIC THERAPY; VHL GENE; MUTATIONS; RISK;
D O I
10.1111/j.1464-410X.2010.09441.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the impact of family history on pathological and clinical outcomes after surgery for clear-cell renal cell carcinoma (ccRCC) in patients with non-syndromic disease. PATIENTS AND METHODS We reviewed 2677 patients treated with radical nephrectomy or nephron-sparing surgery for non-cystic ccRCC between 1970 and 2004 to identify patients with a family history of ccRCC. Patients with von Hippel-Lindau, tuberous sclerosis, or Birt-Hogg-Dube syndrome were excluded from analysis. Demographics and clinico-pathological outcomes were compared to patients with ccRCC without a family history of kidney cancer using chi-squared and Fisher's exact tests. Postoperative cancer-specific survival was estimated using the Kaplan-Meier method. RESULTS We identified 42 patients (1.6%) with a family history of ccRCC who were treated for non-cystic ccRCC, with a median follow-up of 4.7 years (range 1-34). Demographics and tumour characteristics, including tumour stage and grade, were similar between the two groups. Patients with a family history of ccRCC were more likely to have bilateral tumours (11.9 vs 2.2%, P = 0.003). Nevertheless, cancer-specific survival rates for patients with and without a family history of ccRCC were similar at 5 years (75.7 vs 71.1%) and 10 years (53.9 vs 62.2%). CONCLUSIONS Patients with a family history of ccRCC have pathological and clinical outcomes similar to patients with sporadic ccRCC. The increased incidence of bilateral tumours associated with a family history of ccRCC provides further evidence to support a nephron-sparing surgical approach when feasible.
引用
收藏
页码:1638 / 1642
页数:5
相关论文
共 50 条
  • [21] Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma
    Kumar, Aman
    Kumari, Niti
    Rai, Ashutosh
    Singh, Shrawan Kumar
    Kakkar, Nandita
    Prasad, Rajendra
    GENE, 2018, 674 : 31 - 36
  • [22] Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma
    Wei, Xiaona
    Choudhury, Yukti
    Lim, Weng Khong
    Anema, John
    Kahnoski, Richard J.
    Lane, Brian
    Ludlow, John
    Takahashi, Masayuki
    Kanayama, Hiro-omi
    Belldegrun, Arie
    Kim, Hyung L.
    Rogers, Craig
    Nicol, David
    Teh, Bin Tean
    Tan, Min-Han
    SCIENTIFIC REPORTS, 2017, 7
  • [23] Leptin Is Associated with Poor Clinical Outcomes and Promotes Clear Cell Renal Cell Carcinoma Progression
    Fan, Wen-Lang
    Yeh, Yuan-Ming
    Liu, Tsung-Ta
    Lin, Wei-Ming
    Yang, Tse-Yen
    Lee, Chao-Wei
    Lin, Tsung-Chieh
    BIOMOLECULES, 2021, 11 (03) : 1 - 15
  • [24] Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma
    Xiaona Wei
    Yukti Choudhury
    Weng Khong Lim
    John Anema
    Richard J. Kahnoski
    Brian Lane
    John Ludlow
    Masayuki Takahashi
    Hiro-omi Kanayama
    Arie Belldegrun
    Hyung L. Kim
    Craig Rogers
    David Nicol
    Bin Tean Teh
    Min-Han Tan
    Scientific Reports, 7
  • [25] Chemotherapy for non-clear-cell renal cell carcinoma
    David, Kevin A.
    Milowsky, Matthew I.
    Nanus, David M.
    CLINICAL GENITOURINARY CANCER, 2006, 4 (04) : 263 - 268
  • [26] Interaction of germline variants in a family with a history of early-onset clear cell renal cell carcinoma
    Nicolas, Emmanuelle
    Demidova, Elena, V
    Iqbal, Waleed
    Serebriiskii, Ilya G.
    Vlasenkova, Ramilia
    Ghatalia, Pooja
    Zhou, Yan
    Rainey, Kim
    Forman, Andrea F.
    Dunbrack, Roland L., Jr.
    Golemis, Erica A.
    Hall, Michael J.
    Daly, Mary B.
    Arora, Sanjeevani
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (03):
  • [27] Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
    Xu K.Y.
    Wu S.
    Biomarker Research, 3 (1)
  • [28] Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
    Hugues, Marion
    Nerich, V
    Nai, T.
    Paillard, M. J.
    Borowski, L.
    Stein, U.
    Hon, Nguyen Tan T.
    Montcuquet, P.
    Maurina, T.
    Mouillet, G.
    Kleinclauss, F.
    Pivot, X.
    Thiery-Vuillemin, A.
    Limat, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (01) : 271 - 271
  • [29] Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
    Nerich, Virginie
    Hugues, Marion
    Paillard, Marie Justine
    Borowski, Laetitia
    Nai, Thierry
    Stein, Ulrich
    Hon, Thierry Nguyen Tan
    Montcuquet, Philippe
    Maurina, Tristan
    Mouillet, Guillaume
    Kleinclauss, Francois
    Pivot, Xavier
    Limat, Samuel
    Thiery-Vuillemin, Antoine
    ONCOTARGETS AND THERAPY, 2014, 7 : 365 - 374
  • [30] Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma
    An, Josiah
    Packiam, Vignesh T.
    Chennamadhavuni, Adithya
    Richards, Jordan
    Jain, Jayanshu
    Mott, Sarah L.
    Garje, Rohan
    FRONTIERS IN ONCOLOGY, 2022, 11